Douglas T Fearon
Overview
Explore the profile of Douglas T Fearon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
8938
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moresco P, Kastan J, Yang J, Prabakar R, Minicozzi F, Adams D, et al.
bioRxiv
. 2025 Feb;
PMID: 39896665
The exclusion of T cells causes immune escape of pancreatic ductal adenocarcinoma (PDA). T cell exclusion is mediated by the interaction between CXCR4 on T cells and its ligand, CXCL12,...
2.
Li J, Moresco P, Fearon D
Proc Natl Acad Sci U S A
. 2024 Jul;
121(29):e2403917121.
PMID: 38980903
Pancreatic ductal adenocarcinoma (PDA) is a potentially lethal disease lacking effective treatments. Its immunosuppressive tumor microenvironment (TME) allows it to evade host immunosurveillance and limits response to immunotherapy. Here, using...
3.
Maia-Silva D, Cunniff P, Schier A, Skopelitis D, Trousdell M, Moresco P, et al.
Nat Genet
. 2024 Jun;
56(7):1377-1385.
PMID: 38886586
The presence of basal lineage characteristics signifies hyperaggressive human adenocarcinomas of the breast, bladder and pancreas. However, the biochemical mechanisms that maintain this aberrant cell state are poorly understood. Here...
4.
Yao M, Preall J, Yeh J, Pappin D, Cifani P, Zhao Y, et al.
JCI Insight
. 2023 Sep;
8(21.
PMID: 37751306
Intratumoral B cell responses are associated with more favorable clinical outcomes in human pancreatic ductal adenocarcinoma (PDAC). However, the antigens driving these B cell responses are largely unknown. We sought...
5.
Yan R, Moresco P, Gegenhuber B, Fearon D
Cancer Immunol Res
. 2023 Jun;
:OF1-OF11.
PMID: 37285176
Stromal fibroblasts reside in inflammatory tissues that are characterized by either immune suppression or activation. Whether and how fibroblasts adapt to these contrasting microenvironments remains unknown. Cancer-associated fibroblasts (CAF) mediate...
6.
Yan R, Moresco P, Gegenhuber B, Fearon D
Cancer Immunol Res
. 2023 May;
PMID: 37216570
Stromal fibroblasts reside in inflammatory tissues that are characterized by either immune suppression or activation. Whether and how fibroblasts adapt to these contrasting microenvironments remains unknown. Cancer-associated fibroblasts (CAFs) mediate...
7.
Wang Z, Moresco P, Yan R, Li J, Gao Y, Biasci D, et al.
Proc Natl Acad Sci U S A
. 2022 Jan;
119(4).
PMID: 35046049
Cancer immunotherapy frequently fails because most carcinomas have few T cells, suggesting that cancers can suppress T cell infiltration. Here, we show that cancer cells of human pancreatic ductal adenocarcinoma...
8.
Fearon D, Janowitz T
Br J Cancer
. 2021 Mar;
125(2):149-151.
PMID: 33772153
A recent Phase 1 clinical study of the immunological effects of inhibiting the chemokine receptor, CXCR4, in patients with pancreatic ductal adenocarcinoma or colorectal cancer suggests that stimulation of CXCR4...
9.
Biasci D, Smoragiewicz M, Connell C, Wang Z, Gao Y, Thaventhiran J, et al.
Proc Natl Acad Sci U S A
. 2020 Oct;
117(46):28960-28970.
PMID: 33127761
Inhibition of the chemokine receptor CXCR4 in combination with blockade of the PD-1/PD-L1 T cell checkpoint induces T cell infiltration and anticancer responses in murine and human pancreatic cancer. Here...
10.
Fein M, He X, Almeida A, Bruzas E, Pommier A, Yan R, et al.
J Exp Med
. 2020 Jul;
217(10).
PMID: 32667673
C-C chemokine receptor type 2 (CCR2) is expressed on monocytes and facilitates their recruitment to tumors. Though breast cancer cells also express CCR2, its functions in these cells are unclear....